Skip to content

A Safety and Effectiveness Study of a New Contact Lens Cleaning and Disinfecting Solution

A Safety and Effectiveness Study of a New Contact Lens Cleaning and Disinfecting Solution

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02701556
Enrollment
396
Registered
2016-03-08
Start date
2015-05-31
Completion date
2015-10-31
Last updated
2022-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contact Lens Wear

Brief summary

The objective of this study is to evaluate the safety and effectiveness of NNR06 Multi-Purpose Solution cleaning and disinfecting solution (Test) compared to COMPLETE Multi-Purpose Solution cleaning and disinfecting solution (Control) when used by habitual contact lens wearers to bilaterally clean and disinfect their contact lenses for approximately three months.

Detailed description

Approximately 398 subjects (796 eyes) will be enrolled in this three-month controlled, parallel group, masked, randomized study at approximately 22 investigative sites in the United States (US). Approximately one-half of the subjects will be randomized to receive Bausch & Lomb investigational NNR06 Multi-Purpose Solution to be used with a rub care regimen (Test), and approximately one-half of the subjects will be randomized to receive COMPLETE Multi-Purpose Solution with a rub care regimen (Control).

Interventions

DEVICEComplete MPS

a multi-purpose solution for disinfecting, cleaning, conditioning, rinsing, protein removal, and storing soft contact lenses including silicone hydrogel lenses.

DEVICENNR06

an experimental solution for disinfecting, cleaning, conditioning, rinsing, protein removal, and storing soft contact lenses including silicone hydrogel lenses.

Sponsors

Bausch & Lomb Incorporated
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1\. Is a habitual wearer of one of the following lens types: Lens Group Lens Material Trade Name Manufacturer 4 Etafilcon A Acuvue2 Vistakon 5-A Balafilcon A PureVision2 Bausch + Lomb 5-C Samfilcon A Ultra Bausch + Lomb 5-Cm Lotrafilcon B Optix Aqua Alcon 5-Cr Senofilcon A Oasys Vistakon 2\. Is correctable through spherocylindrical refraction to 32 letters (0.3 logMAR) or better (distance, high contrast) in each eye with soft spherical contact lenses. 3\. Has clear central corneas and is free of any anterior segment disorders. 4. Is a habitual user of a lens care product for cleaning, disinfecting, and storage of lenses. 5\. Requires lens correction in both eyes. 6. Wears the same manufacturer and brand of lens in both eyes. 7. Agrees to wear study lenses on a daily wear basis for approximately three months. 8\. Is willing and able to comply with all treatment and follow-up/study procedures.

Exclusion criteria

1\. Has worn gas permeable (GP) lenses within the last 30 days. * 2\. Has worn polymethylmethacrylate (PMMA) lenses within the last three months. 3. Has any systemic disease currently affecting ocular health or which in the Investigator's opinion may have an effect on ocular health during the course of the study. 4\. Currently wears monovision, multifocal, or toric contact lenses. 5. Has ocular astigmatism of 1.00D or greater in either eye. 6. Is not correctable through spherocylindrical refraction to 32 letters (0.3 logMAR) or better (distance, high contrast) in each eye with soft spherical contact lenses. 7\. Has anisometropia (spherical equivalent) of greater than 2.00D 8. Has any grade 2 or greater finding during the slit lamp examination (refer to Appendix B for Methods of Clinical Evaluation). 9\. Has corneal infiltrates, of ANY GRADE. 10. Subjects with any Present finding during the slit lamp examination that, in the Investigator's judgment, interferes with contact lens wear. 11\. Has any scar or neovascularization within the central 4 mm of the cornea. Note that subjects with minor peripheral corneal scarring (that does not extend into the central area), that, in the Investigator's judgment, does not interfere with contact lens wear, are eligible for this study. 12. Is aphakic. 13\. Is amblyopic. 14. Has had any corneal surgery (e.g., refractive surgery). 15. Is allergic to any component in the study care products.

Design outcomes

Primary

MeasureTime frameDescription
The Primary Safety Endpoint Was Statistical Non-inferiority With Respect to the Proportion of Eyes With Any Slit Lamp Findings Greater Than Grade 2 at Any Visit Between the Test and Control Solutions.3 monthsA non-inferiority upper bound of 0.05 (5%) was used to assess the difference (Test - Control) in proportions of slit lamp outcomes. Graded slit lamp findings for each eye were graded for severity on a scale from 0 (No Finding) to 4 (Severe Finding).

Countries

United States

Participant flow

Participants by arm

ArmCount
Bausch & Lomb Investigational NNR06 Multi-Purpose Solution
B & L investigational NNR06 used as a rub care regimen (Test) NNR06: an experimental solution for disinfecting, cleaning, conditioning, rinsing, protein removal, and storing soft contact lenses including silicone hydrogel lenses.
197
COMPLETE Multi-Purpose Solution
B&L Multi-Purpose Solution as a rub care regimen (Control) Complete Multi-Purpose Solution: a multi-purpose solution for disinfecting, cleaning, conditioning, rinsing, protein removal, and storing soft contact lenses including silicone hydrogel lenses.
198
Total395

Baseline characteristics

CharacteristicBausch & Lomb Investigational NNR06 Multi-Purpose SolutionCOMPLETE Multi-Purpose SolutionTotal
Age, Continuous33.2 years
STANDARD_DEVIATION 10
33.7 years
STANDARD_DEVIATION 8.9
33.5 years
STANDARD_DEVIATION 9.4
Region of Enrollment
United States
197 Participants198 Participants395 Participants
Sex: Female, Male
Female
143 Participants142 Participants285 Participants
Sex: Female, Male
Male
54 Participants56 Participants110 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 1970 / 198
serious
Total, serious adverse events
0 / 1970 / 198

Outcome results

Primary

The Primary Safety Endpoint Was Statistical Non-inferiority With Respect to the Proportion of Eyes With Any Slit Lamp Findings Greater Than Grade 2 at Any Visit Between the Test and Control Solutions.

A non-inferiority upper bound of 0.05 (5%) was used to assess the difference (Test - Control) in proportions of slit lamp outcomes. Graded slit lamp findings for each eye were graded for severity on a scale from 0 (No Finding) to 4 (Severe Finding).

Time frame: 3 months

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Bausch & Lomb Investigational NNR06 Multi-Purpose SolutionThe Primary Safety Endpoint Was Statistical Non-inferiority With Respect to the Proportion of Eyes With Any Slit Lamp Findings Greater Than Grade 2 at Any Visit Between the Test and Control Solutions.2 Participants
COMPLETE Multi-Purpose SolutionThe Primary Safety Endpoint Was Statistical Non-inferiority With Respect to the Proportion of Eyes With Any Slit Lamp Findings Greater Than Grade 2 at Any Visit Between the Test and Control Solutions.4 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026